

SERUM INSTITUTE OF INDIA ORDER AND CONTINUED GROWTH IN LIFE SCIENCES PIPELINE

BRISBANE, AUSTRALIA, 29 December 2025: AnteoTech Ltd (ASX: ADO) ('AnteoTech' or 'the Company') is pleased to provide the following update on progress within its Life Sciences business.

Key points:

- Received a US\$185,000 (~AU\$275,750)¹ order for AnteoBind™ from the Serum Institute of India (SII), with despatch to take place on 5th January 2026, on office re-opening.
- SII has agreed to evaluate a new AnteoTech prototype product for use in plate-based ELISA development. Evaluations of this prototype are also about to commence, facilitated with other pharmaceutical and biotechnology customers through distributors.
- New AnteoBind™ sales secured with Japanese customers (~AU\$70,000), reflecting increased market awareness, consistent with the Company's June 2025 strategy.
- Sales pipeline growth continues, with 10 new AnteoBind NXT evaluations initiated since September 2025 across Europe, North America, India and Asia, driven by targeted sales campaigns, conference participation and new marketing materials.
- Progress has been made re-engaging with large global life sciences companies, leveraging longstanding relationships and shared technical expertise, with interest in joint development, commercialisation and direct product supply.
- The first phase of a joint CLIA (chemiluminescent immunoassay) product development program incorporating AnteoBind™ NXT building on successful in-house testing is under discussion as part of re-engaging with a large global life sciences company.
- Comparative studies indicate AnteoBind™ NXT delivers significant performance and cost benefits versus Tosyl chemistry (the most widely used single step coupling chemistry) when used with magnetic particles in CLIA development.
- New Life Sciences products currently under development are expected to see AnteoBind™ transition from an additive to a core ingredient, enabling entry into two of the largest immunoassay life science market segments.
- Three peer-reviewed publications published during the quarter highlighted the ease of use, versatility and performance advantages of AnteoBind™ across immunoassay and diagnostic applications.
- AnteoTech continues to support Vidcare's revised development timelines, while introductions facilitated by Vidcare to other diagnostic developers in India have further strengthened the Company's presence in the growing Indian biotechnology market.

MERRILL GRAY, MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER OF ANTEOTECH COMMENTED:

"These results reflect continued execution of our Life Sciences strategy. The SII order, new customers getting on board and the record number of product evaluations currently underway are all as a direct result of increased customer engagement by the Company's Life Sciences Team who have, both in our established and new markets, created greater awareness of the value that AnteoBind™ delivers. With

¹ <https://www.rba.gov.au/exchange-rates-overview.html> As at 4.00 pm, 24 December 2025 was 0.6709 AU/US

our joint CLIA product development program and interest in our ELISA offering we are moving up the value chain in order to capture greater shareholder value and look forward to accelerated sales growth in 2026 in Life Sciences.”

Serum Institute order and new product prototype testing

AnteoTech on 24th December 2025 received an order from the Serum Institute of India (SII) for US\$185,000 (~AU\$275,275)¹, in line with the five-year supply agreement between the parties. The order has been prepared for fulfilment and will be despatched on 5th January 2026, immediately when the business re-opens after the holidays. Further sales to SII are expected this financial year.

AnteoTech continues to strengthen its relationship with SII and, as part of this engagement, will in January 2026 also provide prototypes of a new AnteoBind™ activated enzyme-linked immunosorbent assay (ELISA) plate product which is currently under development. The ELISA market segment represents approximately 40% of the global immunoassays market, which is valued at approximately US\$21 billion and forecast to grow at approximately 5% CAGR through to 2029.² Successful product development and market entry would therefore represent a material expansion of AnteoTech's addressable market and potential sales base. Product development, prototyping and validation will occur over time, with defined commercial and technical milestones in place. Progress updates will be provided as appropriate.

Expansion of the Life Sciences sales pipeline

In line with the outcomes of the June 2025 strategic review, the Company has focused on generating and advancing priority opportunities through its sales pipeline towards execution. Over recent months, AnteoTech has undertaken a range of targeted market and customer-facing activities, including attendance at key conferences, promotion of a published white paper on AnteoBind™ NXT and the release of additional surface chemistry modification marketing materials.

These activities have resulted in new sales to Japanese customers of approximately AU\$70,000. The sales pipeline has expanded significantly, with a marked increase in customer evaluations within large life sciences and pharmaceutical companies across Europe, the United States as well as Asia. Several of these evaluations are expected to be completed in first half of CY2026, with conversion to sales targeted shortly thereafter.

One targeted sales campaign has focused on India and utilised market-qualified leads provided by the Trade and Investment Queensland (TIQ). AnteoTech's Life Sciences team is scheduled to visit India in February 2026. The visit will include meetings with SII and our Indian distributor, Biogenuix as well as attendance at the BioAsia conference as part of the 2026 TIQ delegation. Further meetings in India will also be supported by Austrade.

The Company has established a program of active re-engagement with large global life sciences companies. Discussions relating to joint product development and associated commercialisation, or the direct purchase of new AnteoTech products under development, for on selling through established global networks, are progressing well. This is significant as it is expected to support AnteoTech's entry into the large and growing CLIA and ELISA markets. Performance and cost reductions are extremely important in these markets. Researchers want ease of use, greater selectivity and overall improved performance and lab managers (purchasers) want cost reductions.

AnteoTech's strategy is to 'move up' the value chain. Specifically, to transition from an additive supplier to a provider of key or core ingredients in ready to use fully integrated products, in turn capturing greater value.

ELISA has been at the forefront of immunoassay development for several decades and remains widely used as a gold-standard methodology across many applications, with the global ELISA market estimated to have a value of US\$21 billion. The CLIA market is estimated to have a value of US\$13 billion and is forecast to grow at around 6% CAGR through to 2029.

AnteoTech is in the early stages of partnering with a large global life sciences company with a significant customer base in the CLIA sector to jointly develop a product for CLIA applications. The first phase of work

² Source: Markets and Markets May 2025 In Vitro Diagnostic Market: Growth, Size, Share and Trends and Confidential Pharmaceutical company. All \$ figures quoted are US\$ billions as at 2024.

is under discussion.

These two new products are expected to position AnteoBind™ within two of the largest segments of the immunoassay market. Incorporation of AnteoBind™ so that it becomes an essential core material in these products represents a step-change for AnteoTech within the industry value chain.

The Company is also progressing the appointment of a new distributor in Japan to support the recent increasing interest and activity in that market, where activity had previously fallen away.

AnteoBind™ benefits further third party validated

The Company has completed internal studies comparing the performance of AnteoBind™ NXT to the tosyl chemistry. Tosylated magnetic particles are widely used in commercial CLIA tests and account for more than 70% of the particles used in both the development and commercial sales of these tests.

AnteoBind™ NXT consistently demonstrated significant savings by reducing antibody use whilst maintaining the sensitivity required for CLIA. Moreover, these results were achieved with a reduction in process time of more than 50% when compared with tosyl chemistry. The results of these studies, together with the demonstrated advantages AnteoBind™ NXT has in CLIA applications, will be published in a white paper in early 2026. This white paper will be shared with CLIA developers as part of our targeted marketing campaigns.

During the last quarter, several peer-reviewed third-party publications citing the use of AnteoBind™ were published including:

- *A Novel Interference-Based Supercritical Angle Fluorescence Biosensor*³
- *Ellagic acid-imbedded MoO₃ nanowires architecture: External mediator-less electrochemical immunoprobeing of inflammatory bowel disease marker*⁴
- *Covalent Linker-Functionalized Nanometer-Thick Gold Film Electrodes for Non-invasive Electrochemical C-Reactive Protein Detection*⁵

The increasing list of peer-reviewed publications supports both the performance benefits of AnteoBind™ and the versatility of its applications. AnteoBind™ has demonstrated potential to enhance existing immunoassay formats, including CLIA, ELISA, lateral flow and Luminex, while also enabling new approaches in point-of-care diagnostics.

The Life Sciences business unit has made, and is expected to continue to make, solid progress. The business is well positioned to secure new sales opportunities and to deliver increasing strategic value as the Company moves into 2026.

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085

For further information, please check our website www.anteotech.com

³ <https://pubs.acs.org/doi/10.1021/acssensors.5c02258>

⁴ <https://www.sciencedirect.com/science/article/abs/pii/S0956566325005937?via%3Dihub>

⁵ <https://pubs.acs.org/doi/10.1021/acsanm.5c04610>

About AnteoTech - (ASX: ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemistry platform technology to develop and commercialise solutions for our global customer base. From our patented cross linker and binder product Anteo X™ to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology business is applying its world-leading engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences business supplies advanced activation materials through our AnteoBind™ suite of products to leading developers and manufacturers of vaccines and diagnostic tests. Our products deliver more sensitive and reproducible results and on incorporation in 'point of care' tests, enable faster, more reliable and accurate test results wherever they are needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs in regard to future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.